Alle Storys
Keine Story von Sequenom, Inc. mehr verpassen.

Sequenom, Inc.

SEQUENOM announces sale of three additional MassARRAY systems, increasing customer installed base of systems to 29 worldwide

San Diego (ots-PRNewswire) -

SEQUENOM(TM), Inc. (Nasdaq: SQNM)
today announced that it has sold three additional MassARRAY systems,
increasing the Company's installed base of systems at customer sites
to 29 worldwide. The three additional sales include the purchase of a
second system by the Whitehead Institute/Centre for Genome Research,
the world's largest public genome research centre, and initial
purchases by Galileo Genomics and an undisclosed party.
SEQUENOM continues to sell MassARRAY systems to leading genomic
and diagnostic companies and institutions, capitalising on the
momentum that started with the product's commercial launch in early
2000. The MassARRAY system is the Company's proprietary platform for
high-throughput analysis of genetic variations, or single nucleotide
polymorphisms (SNPs), and the cornerstone of SEQUENOM's Systems
business unit. The system is also the enabling platform used by the
Company's Genomics business unit for identifying SNPs and genes that
significantly impact health.
"The marketplace has confirmed that our MassARRAY system is the
platform of choice for groups serious about undertaking large-scale
genetic studies," said Toni Schuh, Ph.D., SEQUENOM's President and
Chief Executive Officer. "In the past year, our systems business has
seen demand steadily increase as the leading genomics companies and
research institutions from around the world discover the advantages
of our technology and services.
"Our customers also recognise that we provide a comprehensive
solution for determining the medical utility of SNPs and genes,"
continued Schuh. "This is enabled by our ability to conduct full
genome screens, which is the analysis of many genes in many people.
In addition to the MassARRAY system, our automated assay design
process, the power to combine or pool hundreds of samples in a single
reaction to determine the frequency of genetic markers and an
in-house DNA bank for a control population make such projects a
reality today."
About the Whitehead Institute
The Whitehead Institute is a non-profit, independent basic
research and teaching institution recognised worldwide for
pathfinding programs in cancer and AIDS research, developmental
biology, structural biology, infectious disease, and genetics. The
Institute's mission is to improve human health and welfare and extend
the boundaries of knowledge for future generations.
About Galileo Genomics
Galileo Genomics is a population genomics company dedicated to the
discovery of disease-susceptibility genes in common human diseases
through the application of genetics to founder populations using
cutting-edge technologies. Galileo's research relies on the study of
genetic data collected from the Quebec Founder Population, a
population of 6 million distantly related individuals descended from
a small group of roughly 2,500 common ancestors that arrived from
France between 1608 and 1760.
SEQUENOM is leading a worldwide effort to identify genes and
genetic variations with significant impact on human health. Using its
innovative technologies, information and scientific strategy, the
Company is rapidly translating data generated from the Human Genome
Project into medically important applications. Breaking through the
limitations of traditional research, SEQUENOM's MassARRAY technology,
assay database, population genetics approach and ability to perform
full genome screens are generating results that position SEQUENOM and
its customers and collaborators to quickly capture novel leads to
utilise in new genetics-based diagnostics, drugs and therapies.
All statements in this press release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for SEQUENOM from those projected. Those factors include
risks and uncertainties relating to technological approaches,
dependence on collaborative partners, the specific results generated
and successful performance under these and other collaborative
agreements, product development, manufacturing, market acceptance,
cost and pricing of SEQUENOM products, competition, the intellectual
property of others, patent protection and other risk factors
discussed from time to time in SEQUENOM's reports and filings with
the Securities and Exchange Commission, including SEQUENOM's Annual
Report on Form 10-K for the year ended December 31, 1999 and most
recent Quarterly Report on Form 10-Q. SEQUENOM expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in SEQUENOM's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such
statements are based.
ots Original Text Service: SEQUENOM, Inc.


Abigail Devine, APR, Investor Relations of SEQUENOM, Inc.,
Tel. +1 858 202 9032, e-mail:; or
media, Renee Connolly of Noonan/Russo Communications,
Tel. +1 212-696-4455, ext. 227,e-mail:,
for SEQUENOM, Inc.

Company News On-Call: or
fax, +1 800 758-5804, ext. 124192